Current situation of zalutumumab
作者： Fernando Rivera , Matilde Salcedo , Noelia Vega , Yolanda Blanco , Carlos López
DOI: 10.1517/14712590902932871
关键词:
摘要: Background: Increased EGFR expression has been observed in many tumours. This overexpression usually correlates with a more advanced disease stage, poorer prognosis and worse chemotherapy response. inhibition considered an attractive approach cancer treatment. Various strategies to intervene signalling have developed, mainly receptor of extracellular domain using anti-EGFR monoclonal antibodies on the intracytoplasmic small-molecule tyrosine kinase inhibitors. Cetuximab panitumumab are most developed antibodies, there is plenty published information about their current status Objective/methods: In this review we focus Zalutumumab, IgG1 completely human antibody. Results/conclusions: Apart from inhibition, another anti-neoplastic effect zalutumumab also postulated, mediated by immune mechanisms, specifically antibody-dependent cell cytotoxicity...
informahealthcare.com参考文章(65)
Matthias Peipp, Tanja Schneider-Merck, Michael Dechant, Thomas Beyer, Jeroen J. Lammerts van Bueren, Wim K. Bleeker, Paul W. H. I. Parren, Jan G. J. van de Winkel, Thomas Valerius, Tumor Cell Killing Mechanisms of Epidermal Growth Factor Receptor (EGFR) Antibodies Are Not Affected by Lung Cancer-Associated EGFR Kinase Mutations Journal of Immunology. ,vol. 180, pp. 4338- 4345 ,(2008) , 10.4049/JIMMUNOL.180.6.4338
O Dassonville, J L Formento, M Francoual, A Ramaioli, J Santini, M Schneider, F Demard, G Milano, Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. Journal of Clinical Oncology. ,vol. 11, pp. 1873- 1878 ,(1993) , 10.1200/JCO.1993.11.10.1873
Carlos L. Arteaga, The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. Journal of Clinical Oncology. ,vol. 19, ,(2001)
Fernando Rivera, Maria Eugenia Vega-Villegas, Marta Francisca López-Brea, Cetuximab, its clinical use and future perspectives Anti-Cancer Drugs. ,vol. 19, pp. 99- 113 ,(2008) , 10.1097/CAD.0B013E3282F23287
A.P. Dei Tos, I. Ellis, Assessing epidermal growth factor receptor expression in tumours: What is the value of current test methods? European Journal of Cancer. ,vol. 41, pp. 1383- 1392 ,(2005) , 10.1016/J.EJCA.2005.03.018
Ricardo Hitt, Eva Ciruelos, María L. Amador, Amparo Benito, José J. Sanchez, Claudio Ballestin, Hernán Cortes-Funes, Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy. European Journal of Cancer. ,vol. 41, pp. 453- 460 ,(2005) , 10.1016/J.EJCA.2004.10.014
Jeffrey J. Raizer, HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme Journal of Neuro-oncology. ,vol. 74, pp. 77- 86 ,(2005) , 10.1007/S11060-005-0603-7
Stefania Bellone, Gianluca Frera, Gianpiero Landolfi, Chiara Romani, Elisabetta Bandiera, Germana Tognon, Juan J. Roman, Alexander F. Burnett, Sergio Pecorelli, Alessandro D. Santin, Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: Implications for Cetuximab-mediated therapy in recurrent/metastatic disease Gynecologic Oncology. ,vol. 106, pp. 513- 520 ,(2007) , 10.1016/J.YGYNO.2007.04.028
Paul M Harari, Shyh-Min Huang, None, Searching for reliable epidermal growth factor receptor response predictors: commentary re M. K. Nyati et al., Radiosensitization by pan-ErbB inhibitor CI-1033 in vitro and in vivo. Clin. Cancer Res., 10: 691-700, 2004. Clinical Cancer Research. ,vol. 10, pp. 428- 432 ,(2004) , 10.1158/1078-0432.CCR-1220-03
Mukesh K. Nyati, Meredith A. Morgan, Felix Y. Feng, Theodore S. Lawrence, Integration of EGFR inhibitors with radiochemotherapy Nature Reviews Cancer. ,vol. 6, pp. 876- 885 ,(2006) , 10.1038/NRC1953